cardiovascular disease

And a second webinar this week presented by abcam:

Time:

Thursday, June 16, 2016
3pm-4pm CET / 2pm-3pm GMT / 9am-10am EST

Webinar Overview:

Drug‑induced cardiac injury (DICI) detection remains a major safety issue in drug development. While circulating microRNAs (miRs) have emerged as promising translational biomarkers, novel early detection biomarkers of cardiotoxicity are needed to evaluate toxicity in a time-dependent manner.

This webinar will review: [click to continue…]

{ 0 comments }

Servier selects third cardiovascular target triggering the first milestone under the collaboration

miRagen SERVIER agreementSURESNES, France, and BOULDER, Colo., May 23, 2013 – Servier, a privately-run French research-based pharmaceutical company and a major player in Europe and emerging markets having expertise in the development of treatments for cardiovascular diseases, and miRagen Therapeutics, Inc., a biopharmaceutical company developing innovative microRNA-based therapeutics, announced today that Servier has elected to add a new target as part of its existing agreement for advancing the research, development and commercialization of microRNA-based drug candidates for the treatment of cardiovascular disease.  With this selection, Servier and miRagen now have three microRNA programs under development.

“Our selection of a third target is indicative of the strength of our partnership with miRagen, as well as our shared commitment to develop microRNA-based therapies for the treatment of cardiovascular disease,” said Dr. Jean-Paul Vilaine, Head of Servier’s Cardiovascular Research Unit.  “We look forward to our continued collaboration to advance promising drug candidates.”

For Dr. Jean-Philippe Seta, Chief Executive Officer of Servier, “Micro-RNA is now the gateway to acting at the deepest level of gene expression regulation, with exciting [click to continue…]

{ 0 comments }